OECD Home › Directorate for Financial and Enterprise Affairs › Publications & Documents › Publications
As the demand for food increases, agriculture will continue to attract investment and new actors may be confronted with ethical dilemmas and find it difficult to implement responsible business conduct in their practices. In this context the OECD and the FAO are working together to develop due diligence guidance to help enterprises observe existing widely-supported standards for RBC along agricultural supply chains.
This public consultation is being held to gather comments on the draft FAO-OECD guidance for responsible agricultural supply chains which is designed to help enterprises observe standards of responsible business conduct along their agricultural supply chains. The deadline for comment is 20 February 2015.
Long-term capital is in short supply and has become increasingly so since the 2008 financial crisis. This has profound implications for growth and financial stability. The OECD is exploring these issues in depth.
Adequate infrastructure is necessary for sustainable economic and social development. However investment in infrastructure in most developing and emerging economies needs to be substantially increased. This paper draws on 22 OECD Investment Policy Reviews undertaken in such economies and identifies policy options to enhance the enabling environment for infrastructure investment.
The OECD Trust and Business (TNB) Project is a multidisciplinary and multi-stakeholder initiative that bridges the gap between international rules and standards for how businesses do business and their active implementation.
The OECD has launched a review of the OECD Principles of Corporate Governance to ensure the continuing high quality, relevance and usefulness of the Principles taking into account recent developments in the corporate sector and capital markets.
This page provides a comprehensive overview of OECD work on international investment law published to date.
Entry by generic pharmaceuticals can enhance competition, but innovation should be, at the same time, enhanced by allowing innovators to obtain intellectual property rights on their originator drug. The Competition Committee discussed these issues in June 2014.